You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Insulin Articles
Popular Insulin Articles
Highly Recommended Insulin Articles
Send a link to this page to your friends and colleagues.
Blood glucose control with detemir, a long-acting insulin analog, is better than NPH insulin.
Insulin detemir, manufactured by Novo Nordisk and expected to be a competitor with the long-acting insulin glargine (Lantus), was studied in 408 people with type 1 diabetes for 16 weeks. Insulin detemir was administered twice daily using two different regimens: either before breakfast and at bedtime, or at 12-hour intervals.
NPH insulin was administered before breakfast and at bedtime.
In all treatment groups rapid-acting insulin was administered at mealtimes.
With both detemir-treated groups, fasting blood glucose (BG) improved. The 12-hour-interval group’s BGs were 27 mg/dl lower than the NPH-treated group’s, and the before-breakfast and bedtime-determir group was 40 mg/dl lower than the NPH-treated group.
The risk of minor hypoglycemia was lower in both detemir-treated groups.
—Diabetes Care, May 2004
0 comments - Jul 1, 2004
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.